Director's Share Purchase

RNS Number : 6144G
Oxford Biomedica PLC
10 June 2013
 

Oxford BioMedica plc

Director's Share Purchase

 

 

Oxford, UK - 10 June 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 7 June 2013 that six of its Directors had acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 

 

 

 

 

Interest after purchase

Director / PDMR

Title

Price per share (p)

Number of Ordinary Shares acquired on

07 June 2013

Number of Ordinary Shares

% of total

issued share capital

Paul Blake

NED

1.750

113,097

533,097

0.037%

John Dawson

CEO

1.750

282,829

2,282,829

0.161%

Andrew Heath

NED

1.789

180,000

500,000

0.035%

Peter Nolan

SVP

1.750

169,675

733,313

0.052%

Nick Rodgers

Chairman

1.750

282,829

634,829

0.045%

Timothy Watts

CFO

1.750

282,829

3,282,829

0.232%

 

The issued share capital of the Company is 1,416,149,005 1p ordinary shares.

 

-Ends-

 

For further information, please contact:

 

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

Nomura Code Securities Limited:

Juliet Thompson/Jonathan Senior/Christopher Golden

Tel: +44 (0)20 7776 1200

Media Enquiries:

Mary-Jane Elliott/Sarah Macleod/Claire Dickinson

M:Communications

 

 

Tel: +44 (0)20 7920 2360

 

 

Notes to editors

 

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSQDLFBXQFLBBE